Literature DB >> 18332285

Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates.

Kent R Bailey1, Brandon R Grossardt, John W Graves.   

Abstract

Despite 40 years of research demonstrating the efficacy of antihypertensive medications for lowering blood pressure and decreasing cardiovascular disease, hypertension control rates worldwide remain low. We explored here how both medication efficacy rates and patient/physician decision-making (discontinuation rates) affect overall hypertension control rates. To do this we introduced the use of Kaplan-Meier methodology to predict hypertension control rates separately within age strata. An important aspect of our analysis is the use of a "treatment intensity score," including both the number of agent(s) and the percentage of maximal dose of agent(s). We investigated how blood pressure control rates vary with age, gender, and treatment intensity. Our analysis found that both efficacy and discontinuation rates at different treatment intensities vary with age and gender, so that for each increase in age by 1 decade, the log hazard of achieving controlled blood pressure at any given intensity decreases by 0.10 in men and 0.20 in women. Overall hypertension control rates ranged from 80.8% for persons age 15 to 39 years to only 42.1% for persons age >/=80 years. Our analysis more accurately represents achievable hypertension control rates, with differences by gender, than previous work, because we investigated the contributions of efficacy and treatment aggressiveness in the control of hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332285      PMCID: PMC2655216          DOI: 10.1161/HYPERTENSIONAHA.107.101659

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  23 in total

1.  Prevalence, awareness, treatment, and control of hypertension in china.

Authors:  Dongfeng Gu; Kristi Reynolds; Xigui Wu; Jing Chen; Xiufang Duan; Paul Muntner; Guanyong Huang; Robert F Reynolds; Shaoyong Su; Paul K Whelton; Jiang He
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  An observational study of the medical events associated with clinician-initiated changes in treatment for essential hypertension.

Authors:  G Brokensha; J E Marley
Journal:  J Hum Hypertens       Date:  2001-06       Impact factor: 3.012

3.  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors: 
Journal:  JAMA       Date:  1967-12-11       Impact factor: 56.272

4.  Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States.

Authors:  Y Richard Wang; G Caleb Alexander; Randall S Stafford
Journal:  Arch Intern Med       Date:  2007-01-22

5.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

6.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

7.  Physician-related barriers to the effective management of uncontrolled hypertension.

Authors:  Susan A Oliveria; Pablo Lapuerta; Bruce D McCarthy; Gilbert J L'Italien; Dan R Berlowitz; Steven M Asch
Journal:  Arch Intern Med       Date:  2002-02-25

8.  Factors related to non-compliance with antihypertensive drug therapy.

Authors:  E Jokisalo; E Kumpusalo; H Enlund; P Halonen; J Takala
Journal:  J Hum Hypertens       Date:  2002-08       Impact factor: 3.012

9.  A population-based European cohort study of persistence in newly diagnosed hypertensive patients.

Authors:  J Hasford; A Mimran; W R Simons
Journal:  J Hum Hypertens       Date:  2002-08       Impact factor: 3.012

10.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.

Authors:  M R Law; N J Wald; J K Morris; R E Jordan
Journal:  BMJ       Date:  2003-06-28
View more
  13 in total

1.  Microalbuminuria and left ventricular mass in overweight and obese hypertensive patients: role of the metabolic syndrome.

Authors:  Federico Guerra; Lucia Mancinelli; Alessia Buglioni; Valentina Pierini; Alessandro Rappelli; Paolo Dessì-Fulgheri; Riccardo Sarzani
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-12-01

Review 2.  Hypertension in Young People: Epidemiology, Diagnostic Assessment and Therapeutic Approach.

Authors:  Allegra Battistoni; Flaminia Canichella; Giulia Pignatelli; Andrea Ferrucci; Giuliano Tocci; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-07-08

3.  Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update.

Authors:  Maurizio Destro; Francesca Cagnoni; Antonio D'Ospina; Alessandra Rossi Ricci; Elena Demichele; Emmanouil Peros; Augusto Zaninelli; Paola Preti
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

4.  Primary hypertension at a single center: treatment, time to control, and extended follow-up.

Authors:  Amy DiPietro; Deborah Kees-Folts; Susan DesHarnais; Fabian Camacho; Steven Joel Wassner
Journal:  Pediatr Nephrol       Date:  2009-12       Impact factor: 3.714

5.  Antihypertensive medication initiation among young adults with regular primary care use.

Authors:  Heather M Johnson; Carolyn T Thorpe; Christie M Bartels; Jessica R Schumacher; Mari Palta; Nancy Pandhi; Ann M Sheehy; Maureen A Smith
Journal:  J Gen Intern Med       Date:  2014-02-04       Impact factor: 5.128

6.  Ten-year changes in ambulatory blood pressure: The prognostic value of ambulatory pulse pressure.

Authors:  Paolo Balietti; Francesco Spannella; Federico Giulietti; Giulia Rosettani; Beatrice Bernardi; Guido Cocci; Anna R Bonfigli; Riccardo Sarzani
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-07-07       Impact factor: 3.738

7.  Fixed-dosed combinations are not indicated as initial therapy: a debate.

Authors:  Barry L Carter
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-02       Impact factor: 3.738

8.  Associations between body mass index, ambulatory blood pressure findings, and changes in cardiac structure: relevance of pulse and nighttime pressures.

Authors:  Massimiliano Fedecostante; Francesco Spannella; Federico Giulietti; Emma Espinosa; Paolo Dessì-Fulgheri; Riccardo Sarzani
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-01-05       Impact factor: 3.738

9.  The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients.

Authors:  Federico Guerra; Lucia Mancinelli; Luca Angelini; Marco Fortunati; Alessandro Rappelli; Paolo Dessì-Fulgheri; Riccardo Sarzani
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

Review 10.  Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.

Authors:  Ivo Abraham; Karen MacDonald; Christine Hermans; Ann Aerts; Christopher Lee; Heidi Brié; Stefaan Vancayzeele
Journal:  Vasc Health Risk Manag       Date:  2011-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.